Evaluation of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma and Ocular Hypertension

NCT ID: NCT02207621

Last Updated: 2018-04-06

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 756 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-07-31
• Study Completion Date: 2016-03-31

Brief Summary

Evaluation of the ocular hypotensive efficacy and safety of Netarsudil (AR-13324) Ophthalmic Solution compared to Timolol Maleate Ophthalmic Solution

Conditions

Ocular Hypertension; Open-angle Glaucoma

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

AR-13324 Ophthalmic Solution 0.02% & placebo

1 drop AR-13324 in the evening (PM) \& 1 drop placebo in the morning (AM) in both eyes (OU)

Group Type: EXPERIMENTAL

AR-13324 Ophthalmic Solution 0.02%

Intervention Type: DRUG

1 drop once daily (QD), PM, OU

Placebo

Intervention Type: OTHER

1 drop QD, AM, OU

Timolol maleate Ophthalmic Solution 0.5% BID

1 drop twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)

Group Type: ACTIVE_COMPARATOR

Timolol maleate Ophthalmic Solution 0.5% BID

Intervention Type: DRUG

1 drop BID, AM/PM, OU

AR-13324 Ophthalmic Solution 0.02% BID

1 drop AR-13324 twice daily (BID) in the morning (AM) and evening (PM) in both eyes (OU)

Group Type: EXPERIMENTAL

AR-13324 Ophthalmic Solution 0.02% BID

Intervention Type: DRUG

1 drop BID, AM/PM, OU

Interventions

AR-13324 Ophthalmic Solution 0.02%

1 drop once daily (QD), PM, OU

Intervention Type: DRUG

Timolol maleate Ophthalmic Solution 0.5% BID

1 drop BID, AM/PM, OU

Intervention Type: DRUG

Placebo

1 drop QD, AM, OU

Intervention Type: OTHER

AR-13324 Ophthalmic Solution 0.02% BID

1 drop BID, AM/PM, OU

Intervention Type: DRUG

Other Intervention Names

Netarsudil; Netarsudil

Eligibility Criteria

Inclusion Criteria

1. 0-2 years of age and 18 years or greater

2. Diagnosis of open angle glaucoma or ocular hypertension

3. Unmedicated (post-washout) intraocular pressure (IOP) >20 mm Hg and < 27 mm Hg in the study eye at 2 qualification visits

4. Corrected visual acuity in each eye equivalent to 20/200

5. Able and willing to give signed informed consent (parent or guardian consent for pediatric patient) and follow study instructions

Exclusion Criteria

Ophthalmic:

1. Glaucoma: pseudoexfoliation or pigment dispersion component, history of angle closure, or narrow angles. Note: Previous laser peripheral iridotomy is NOT acceptable.

2. Intraocular pressure ≥27 mm Hg (unmedicated) in both eyes or use of more than two ocular hypotensive medications within 30 days of screening. Note: fixed dose combinations count as two medications.

3. Known hypersensitivity to any component of the formulations to be used (benzalkonium chloride, etc.), to topical anesthetics or beta-adrenoceptor antagonists.

4. Previous glaucoma intraocular surgery or glaucoma laser procedures in either eye

5. Refractive surgery in either eye.

6. Ocular trauma in either eye within the six months prior to screening, or ocular surgery or non-refractive laser treatment within the three months prior to screening.

7. Recent or current evidence of ocular infection or inflammation in either eye. Current evidence of clinically significant blepharitis, conjunctivitis, or a history of herpes simplex or zoster keratitis at screening in either eye.

8. Ocular medication in either eye of any kind within 30 days of screening.

9. Clinically significant ocular disease in either eye (e.g., corneal edema, uveitis, severe keratoconjunctivitis sicca) which might interfere with the study, including glaucomatous damage so severe that washout of ocular hypotensive medications for one month is not judged safe.

10. Central corneal thickness in either eye greater than 600 µm at screening.

11. Any abnormality in either eye preventing reliable applanation tonometry of either eye.

Systemic:

12. Clinically relevant abnormalities (as determined by the investigator) in laboratory tests at screening which may impact the study.

13. Known hypersensitivity or contraindication to beta-adrenoceptor antagonists (e.g., chronic obstructive pulmonary disease or bronchial asthma; abnormally low blood pressure or heart rate; second or third degree heart block or congestive heart failure; severe diabetes).

14. Clinically significant systemic disease (e.g., uncontrolled diabetes, myasthenia gravis, hepatic, renal, endocrine or cardiovascular disorders) which might interfere with the study.

15. Participation in any investigational study within 30 days prior to screening.

16. Changes of systemic medication that could have an effect on intraocular pressure within 30 days prior to screening, or anticipated during the study.

17. Women of childbearing potential who are pregnant, nursing, planning a pregnancy, or not using a medically acceptable form of birth control. An adult woman is considered to be of childbearing potential unless she is one year post-menopausal or three months post-surgical sterilization. All females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must not intend to become pregnant during the study..

• Maximum Eligible Age: 99 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Aerie Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Theresa Heah, MD

Role: STUDY_DIRECTOR

Aerie Pharmaceuticals, Inc.

Locations

Aerie Pharmaceuticals

Bedminster, New Jersey, United States

Countries

United States

References

Mundorf T, Mah F, Sheng H, Heah T. Effects of Netarsudil on the Corneal Endothelium: Three-Month Findings from a Phase 3 Trial. Ophthalmol Glaucoma. 2020 Nov-Dec;3(6):421-425. doi: 10.1016/j.ogla.2020.04.014. Epub 2020 Apr 29.

Reference Type: DERIVED

PMID: 33250082 (View on PubMed)

Other Identifiers

AR-13324-CS302

Identifier Type: -

Identifier Source: org_study_id